Boulevard Bio

Boulevard Bio is a biotechnology company focused on the discovery and development of novel gut-derived peptide therapeutics for metabolic diseases. The company utilizes a proprietary platform to identify previously unknown hormones and secreted factors from the human gut that play critical roles in systemic energy balance and glucose regulation. By targeting the gut-brain and gut-liver axes, Boulevard Bio aims to develop next-generation treatments for obesity and type 2 diabetes. The leadership team includes prominent experts in genomics and metabolic research, including founders from Stanford University and former Eli Lilly scientists. The company leverages advanced multi-omics discovery tools to map the gut secretome and identify high-potential therapeutic candidates. Currently in the pre-clinical stage, Boulevard Bio is advancing a pipeline of innovative biologics designed to offer superior efficacy and safety profiles.